top of page

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Updated: Feb 15, 2022

Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019.


FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib

3 views0 comments
bottom of page